Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Websiteseragonpharm.com
CategoryBioTech
Phone(858) 369-7600
Emailinfo@Seragonpharm...
Employees
Founded2013

Offices

San Diego, USA
12780 El Camino Real
Suite #302
San Diego, CA, 92130
USA

People

President and CEO

Funding

TOTAL $30M
FUNDING TOTAL $30M
Series A, 10/2013
$30M

Tags

Seragon Pharmaceuticals

Seragon Pharmaceuticals’ orally active selective estrogen receptor degraders (SERDs) represent a potential new treatment for progressive metastatic breast cancer that may circumvent the problem of resistance to anti-hormonal therapies. SERDs are estrogen receptor antagonists that also induce a conformational change that results in the degradation of the receptor. Seragon has identified multiple SERDs that have pharmacokinetic profiles sufficient to drive a robust therapeutic response and result in degradation of the receptor and anti-tumor activity. The novel profile of these potent, orally bioavailable, nonsteroidal agents may result in greater efficacy and response rates in patients with hormone-refractory breast cancer compared to other drugs in development. Seragon’s most advanced leads induce tumor regressions in both tamoxifen sensitive and tamoxifen resistant tumor models in vivo. Based on these results and others, the company is currently advancing multiple, distinct lead SERD chemical scaffolds toward clinical development. Seragon’s SERDs are initially being developed for the treatment of women with late-stage, progressive metastatic disease.

Recent Milestones

Videos

Screenshots

Seragon Pharmaceuticals screenshot
Above: Homepage
Uploaded: 10/17/13

Sources

  1. Seragon Pharmaceuticals Raises $30M in Series A Financing (seragonpharm.com) [edit]
Edit This Page
Last Edited 12/20/13

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize ยป

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy